Arpan Desai
Arpan Desai
Managing Director
NanoVation Therapeutics UK
Graham Hayes
Graham Hayes, PhD
Senior Scientist
NanoVation Therapeutics UK
Ben Knappett,
Ben Knappett, PhD
Product Manager, LNP Solutions
Unchained Labs

Broadcast Date: 
  • Time: 

Lipid nanoparticle (LNP)-based mRNA technology enabled the rapid development of COVID-19 vaccines resulting in unprecedented interest in the technology’s potential. Many researchers approach the design issue via systematic optimization of lipidic components such as the ionizable lipid, PEG lipid, structural and helper lipids. However, these approaches are limited by the low-throughput and high cost of LNP preparation.

In this GEN webinar, our expert speakers will discuss strategies and tools for rapidly formulating and characterizing LNPs for drug discovery and development. They will share results from a collaboration between Unchained Labs and NanoVation Therapeutics UK to evaluate instrumentation for high throughput-controlled manufacture of LNPs at small scales and demonstrate how their findings will accelerate the creation of LNP-based medicines.  

A live Q&A session will follow the presentation, offering you a chance to pose questions to our expert panelists.

Produced with support from: